Aerosolized Antibiotics
Copyright © 2015 by Daedalus Enterprises..
Administration of medications via aerosolization is potentially an ideal strategy to treat airway diseases. This delivery method ensures high concentrations of the medication in the targeted tissues, the airways, with generally lower systemic absorption and systemic adverse effects. Aerosolized antibiotics have been tested as treatment for bacterial infections in patients with cystic fibrosis (CF), non-CF bronchiectasis (NCFB), and ventilator-associated pneumonia (VAP). The most successful application of this to date is treatment of infections in patients with CF. It has been hypothesized that similar success would be seen in NCFB and in difficult-to-treat hospital-acquired infections such as VAP. This review summarizes the available evidence supporting the use of aerosolized antibiotics and addresses the specific considerations that clinicians should recognize when prescribing an aerosolized antibiotic for patients with CF, NCFB, and VAP.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2015 |
---|---|
Erschienen: |
2015 |
Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
---|---|
Enthalten in: |
Respiratory care - 60(2015), 6 vom: 24. Juni, Seite 762-1; discussion 771-3 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Restrepo, Marcos I [VerfasserIn] |
---|
Links: |
---|
Themen: |
Aerosols |
---|
Anmerkungen: |
Date Completed 22.03.2016 Date Revised 13.06.2015 published: Print Citation Status MEDLINE |
---|
doi: |
10.4187/respcare.04208 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM249920530 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM249920530 | ||
003 | DE-627 | ||
005 | 20231224154624.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2015 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.4187/respcare.04208 |2 doi | |
028 | 5 | 2 | |a pubmed24n0833.xml |
035 | |a (DE-627)NLM249920530 | ||
035 | |a (NLM)26070573 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Restrepo, Marcos I |e verfasserin |4 aut | |
245 | 1 | 0 | |a Aerosolized Antibiotics |
264 | 1 | |c 2015 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 22.03.2016 | ||
500 | |a Date Revised 13.06.2015 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2015 by Daedalus Enterprises. | ||
520 | |a Administration of medications via aerosolization is potentially an ideal strategy to treat airway diseases. This delivery method ensures high concentrations of the medication in the targeted tissues, the airways, with generally lower systemic absorption and systemic adverse effects. Aerosolized antibiotics have been tested as treatment for bacterial infections in patients with cystic fibrosis (CF), non-CF bronchiectasis (NCFB), and ventilator-associated pneumonia (VAP). The most successful application of this to date is treatment of infections in patients with CF. It has been hypothesized that similar success would be seen in NCFB and in difficult-to-treat hospital-acquired infections such as VAP. This review summarizes the available evidence supporting the use of aerosolized antibiotics and addresses the specific considerations that clinicians should recognize when prescribing an aerosolized antibiotic for patients with CF, NCFB, and VAP | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a aerosols | |
650 | 4 | |a antibacterial agents | |
650 | 4 | |a bronchiectasis | |
650 | 4 | |a cystic fibrosis (CF) | |
650 | 4 | |a ventilator-associated pneumonia (VAP) | |
650 | 7 | |a Aerosols |2 NLM | |
650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
700 | 1 | |a Keyt, Holly |e verfasserin |4 aut | |
700 | 1 | |a Reyes, Luis F |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Respiratory care |d 1974 |g 60(2015), 6 vom: 24. Juni, Seite 762-1; discussion 771-3 |w (DE-627)NLM07486520X |x 1943-3654 |7 nnns |
773 | 1 | 8 | |g volume:60 |g year:2015 |g number:6 |g day:24 |g month:06 |g pages:762-1; discussion 771-3 |
856 | 4 | 0 | |u http://dx.doi.org/10.4187/respcare.04208 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 60 |j 2015 |e 6 |b 24 |c 06 |h 762-1; discussion 771-3 |